Oscar Hernandez-Alba
Overview
Explore the profile of Oscar Hernandez-Alba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benazza R, Letissier L, Papadakos G, Thom J, Diemer H, Cotton G, et al.
Anal Chem
. 2025 Jan;
97(5):2639-2647.
PMID: 39889214
Even though mAbs have attracted the biggest interest in the development of therapeutic proteins, next-generation therapeutics such as single-domain antibodies (sdAb) are propelling increasing attention as new alternatives with appealing...
2.
Gervason S, Dutkiewicz R, Want K, Benazza R, Mor-Gautier R, Grabinska-Rogala A, et al.
Nat Chem Biol
. 2025 Jan;
PMID: 39870763
Iron-sulfur clusters are essential metallocofactors synthesized by multiprotein machineries via an unclear multistep process. Here we report a step-by-step dissection of the [2Fe-2S] cluster assembly process by the Escherichia coli...
3.
Boos A, Most J, Cahuzac H, Moreira da Silva L, Daubeuf F, Erb S, et al.
J Med Chem
. 2024 Dec;
68(1):695-705.
PMID: 39680648
Antibody-drug conjugates (ADCs) are a well-established class of therapeutics primarily used in oncology to selectively deliver highly cytotoxic agents into cancer cells. While ADCs should theoretically spare healthy tissues and...
4.
Reinert T, Houze P, Mignet N, Naghizade A, Alez-Martin L, Hernandez-Alba O, et al.
Anal Chem
. 2024 Nov;
96(49):19286-19293.
PMID: 39600236
Monoclonal antibody (mAbs) therapeutics cannot evade the occurrence of adverse effects. Thus, mAbs are commonly triggering immune responses corresponding to the expression of antidrug antibodies. Antidrug antibodies can neutralize mAbs,...
5.
Shajan I, Rochet L, Tracey S, Benazza R, Jackowska B, Hernandez-Alba O, et al.
Bioconjug Chem
. 2024 Sep;
PMID: 39284580
Redirecting T cells to tumor cells by bispecific antibodies is an effective approach to treat cancer, and T cell-dependent bispecific antibodies (TDBAs) are an emerging class of potent immunotherapeutic agents....
6.
Vaur V, Koutsopetras I, Erb S, Jackowska B, Benazza R, Cahuzac H, et al.
Chembiochem
. 2024 May;
25(19):e202400170.
PMID: 38713134
Bispecific antibodies (bsAbs) have recently emerged as a promising platform for the treatment of several conditions, most importantly cancer. Based on the combination of two different antigen-binding motifs in a...
7.
Gizardin-Fredon H, Santo P, Chagot M, Charpentier B, Bandeiras T, Manival X, et al.
Nat Commun
. 2024 Apr;
15(1):3516.
PMID: 38664367
Chemical cross-linking reactions (XL) are an important strategy for studying protein-protein interactions (PPIs), including low abundant sub-complexes, in structural biology. However, choosing XL reagents and conditions is laborious and mostly...
8.
Benazza R, Koutsopetras I, Vaur V, Chaubet G, Hernandez-Alba O, Cianferani S
Talanta
. 2024 Feb;
272:125727.
PMID: 38364570
Disulfide rebridging methods are emerging recently as new ways to specifically modify antibody-based entities and produce future conjugates. Briefly, the solvent-accessible disulfide bonds of antibodies or antigen-binding fragments (Fab) thereof...
9.
Koutsopetras I, Vaur V, Benazza R, Diemer H, Sornay C, Ersoy Y, et al.
Chemistry
. 2023 Dec;
30(14):e202303242.
PMID: 38050774
The chemical bioconjugation of proteins has seen tremendous applications in the past decades, with the booming of antibody-drug conjugates and their use in oncology. While genetic engineering has permitted to...
10.
Beaumal C, Desligniere E, Diemer H, Carapito C, Cianferani S, Hernandez-Alba O
Anal Bioanal Chem
. 2023 Nov;
416(2):519-532.
PMID: 38008785
Antibody-drug conjugates (ADCs) are highly complex proteins mainly due to the structural microvariability of the mAb, along with the additional heterogeneity afforded by the bioconjugation process. Top-down (TD) and middle-down...